Cysteine-based regulation of redox-sensitive Ras small GTPases

Samantha Messina*, Giovanna De Simone, Paolo Ascenzi

Department of Science, Roma Tre University, Viale Guglielmo Marconi 446, I-00146, Roma, Italy

ARTICLE INFO

Keywords:
Ras small GTPases
Cysteine 118
Redox-signalling

ABSTRACT

Reactive oxygen and nitrogen species (ROS and RNS, respectively) activate the redox-sensitive Ras small GTPases. The three canonical genes (HRAS, NRAS, and KRAS) are archetypes of the superfamily of small GTPases and are the most common oncogenes in human cancer. Oncogenic Ras is intimately linked to redox biology, mainly in the context of tumorigenesis. The Ras protein structure is highly conserved, especially in effector-binding regions. Ras small GTPases are redox-sensitive proteins thanks to the presence of the NKCD motif (Asn116-Lys117-Cys118-Asp119). Notably, the ROS- and RNS-based oxidation of Cys118 affects protein stability, activity, and localization, and protein-protein interactions. Cys residues at positions 80, 181, 184, and 186 may also help modulate these actions. Moreover, oncogenic mutations of Gly12Cys and Gly13Cys may introduce additional oxidative centres and represent actionable drug targets. Here, the pathophysiological involvement of Cys-redox regulation of Ras proteins is reviewed in the context of cancer and heart and brain diseases.

1. Introduction

Various studies support the notion that Ras GTPases are regulated by reactive oxygen and nitrogen species [1–6]. Redox signalling is a form of signal transduction that progresses through the reversible oxidation of cysteines in proteins, mostly mediated by hydrogen peroxide as a second messenger. Few members of the small GTPase family are redox sensitive (H-Ras, N-Ras, K-Ras, E-Ras, Rap1A and Rap1B and some Rab proteins) and their known conserved redox-sensitive sequence, the NKCD amino acid sequence (Asn116-Lys117-Cys118-Asp119), is located in the G-domain and is virtually identical in all proteins containing this motif. Oxidation of specific amino acid residues in many small GTPases affects protein stability, activity, localization and protein-protein interactions [4]. Moreover, the observation that many oncogenes, such as RAS, and many tumour suppressor proteins, such as p53, can directly or indirectly alter the redox state of a cell [7–10] reinforced the link between RAS redox circuitries and cancer.

Chemical modifications of Ras proteins consist of post-translational modifications occurring at the hypervariable region (HVR); in particular, Cys residues undergo farnesylation and palmitoylation. Other chemical modifications such as phosphorylation, ubiquitination and oxidation (S-glutathionylation, S-nitrosylation) involve the entire Ras sequence and are highly specific. These modifications induce distinct sensitivity, which is exhibited by individual Ras isoforms and their functional interactions with direct and/or downstream effectors. Notably, the direct effects of endogenous redox agents on these small GTPases perturb GTPase nucleotide-binding interactions that result in the enhancement of the guanine nucleotide exchange rate of these enzymes [11,12] (Table 1).

Several excellent reviews have recently been published that describe the biochemistry of Ras redox signalling in deep detail [3–6,24]. This review focuses on the Cys80-, Cys118-, Cys181-, Cys184-, and Cys186-based redox signalling of the Ras small GTPases by highlighting the differences between the four Ras isoforms and their cellular consequences. Pathophysiological involvement of this redox regulation of native Ras proteins is discussed in the context of cancer and in heart and brain diseases. Moreover, oncogenic mutation of Gly12Cys and Gly13Cys may introduce additional oxidative centres and represent actionable drug targets. Downstream signalling, such as that involving IP3K or MAPK, and the in-depth chemical analysis of redox signalling are not a major focus of this review.

2. RAS proteins structure

All Ras proteins consist of 188 or 189 amino acid residues with a molecular weight of approximately 21 kDa. K-Ras, H-Ras and N-Ras display two domains: (i) the catalytic domain (G domain), which corresponds to the amino acid residues 1–166; and (ii) the hypervariable region (HVR), which corresponds to residues 167–189 [25]. The G domain is characterized by five motifs (G1-G5). The G1-G3 motifs build up the effector lobe (amino acids 1–86) containing the Switch subdomains, I and II (residues 32–38 and 60–75, respectively); the

* Corresponding author.
E-mail address: samantha.messina@uniroma1.it (S. Messina).

https://doi.org/10.1016/j.redox.2019.101282
Received 3 June 2019; Received in revised form 21 July 2019; Accepted 24 July 2019
Available online 25 July 2019

© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
sequence identity of G1-G3 is 100% in all family members. On the other hand, the G4 (NKCD; i.e., Asn116-Lys 117-Cys118-Asp119) and G5 (ETSACK; i.e., Glu143-Thr144-Ser145-Ala146-Lys 147) motifs build up the allosteric lobe (amino acids 87–166); the sequence identity is 82% among all family members [26]. The amino acid sequence of the C-terminal HVR domain (amino acids 167–189) is highly flexible and divergent among the Ras proteins, except for the CAAX motif (i.e., Cys185-Aaa186-Aaa187-Xxx188; where Aaa is an aliphatic amino acid residue) [27,29,30]. The Cys118 residue, located in the NKCD region, located consensus in all Ras small GTPases [31]. The Cys118 residue (present in the NKCD region, located amino acid 167–189) is highly reactive towards oxidative species and their molecular consequences in the membrane anchoring of farnesylated H-Ras, N-Ras, K-Ras4A and K-Ras4B, in which the Cys residues are the major players [29,44]. In detail, a farnesyI group is covalently attached to Cys186 in the CAAX motif by farnesyltransferase. This prenylation reaction is followed by (i) the proteolytic removal of the AAX tripeptide (i.e., Ile/Val/Ile/Leu/Val/Xxx) by Ras-converting enzyme-1 (RCE1), and (ii) the subsequent carboxymethylation of the resulting C-terminal Cys by isoprenylcysteine carboxymethyltransferase-1 (ICMT1). In addition, the palmitoylation of Cys residue(s) adjacent to the CAAX motif by a palmitoyltransferase stabilizes the membrane anchoring of farnesylated H-Ras, N-Ras, and K-Ras4A (Hancock et al., 2003). The palmitoylation-depalmitoylation process of the C-terminal residues of H-Ras modulates the protein transit from the Golgi to the plasma membrane [45]. Notably, phosphorylation, ubiquitination and acetylation play a minor role on the subcellular localization of H-Ras, N-Ras, K-Ras4A and K-Ras4B [46–50]. In particular, K-Ras is monoubiquitinated at Lys147 [48] and phosphorylated at Ser 181 [28,51,52], H-Ras is ubiquitinated at Lys117 [53], K-Ras4B is acetylated at Lys104 [47], and N-RAS is phosphorylated at Tyr32 [49]. However, the poly-Lys stretch of the HVR region of K-Ras4B allows its recruitment to the inner leaflet of the acidic plasma membrane by electrostatic interactions [27,54].

4. Cysteine-based redox regulation of RAS isoforms

The oxidation of Ras protein Cys residue(s) affects protein stability, activity, localization and protein-protein interactions (Tables 1 and 2).

4.1. Cys118

Although the Cys118 residue (present in the NKCD region, located invariant N-terminal domain up to amino acid 166) is considered the primary target of ROS and RNS [12–17], the involvement of this residue in the redox-based modulation is controversial. Conflicting results likely reflect the use of different methodological approaches, redox inducers, and cell lines (Table 1).

In 1995, nitric oxide (NO) was reported, for the first time, to modulate Ras activation in human T cells, by Cys118 S-nitrosylation, promoting guanine nucleotide exchange [59]. This finding was later confirmed by structural and biochemical studies on the purified H-Ras protein [16,60]. Further, eNOS has been reported to selectively activate N-Ras, but not K-Ras, at the Golgi of T cells via Cys118 S-nitrosylation. Notably, the activation at the Golgi has been shown to facilitate the positive selection of T cells, whereas N-Ras activation at the plasma membrane has been reported to induce the negative selection of T cells [17]. Further, in mouse brain development, the iNOS-dependent S-nitrosylation of Cys118 of H-Ras has been shown to induce neurogenic
4.2. Other Cys residues

As the primary mediator of membrane attachment, the HVR domain has a significant influence on isoform-specific behaviour. Although Cys181, Cys184 and Cys186 are known to be modified by attached lipid molecules in intact cells, these reactive Cys residues may undergo oxidation and nitrosylation during normal and pathological cellular events. In particular, S-glutathionylation of H-Ras plays a critical role in Angiotensin II (AII)-induced hypertrophic signalling of cultured vascular smooth muscle cells (VSMC). MALDI-TOF mass spectrometry provided evidence that three modification sites are present on H-Ras at the C-terminal Cys80, Cys181, and Cys186. However, Cys118-nitrosylation was not detected by mass spectrometry probably because NO is not involved in AII signalling in VSMCs [11]. In addition, ROS directly alters protein palmitoylation by oxidizing the C-terminal Cys residues in a mouse model of metabolic syndrome. Specifically, in a high-fat-diet animal model, decreased H-Ras palmitoylation reflected the oxidation of the Cys181 and Cys184 residues. This induces H-Ras inactivation by trapping it at the Golgi and preventing physiological signalling by RAF-1 kinase [18]. The isoform specificity is a critical issue from the structural viewpoint as the HVR has been only partially characterized. In fact, the oxidation of Cys residues 181, 184 and 186 was identified by MALDI-TOF analysis only in H-Ras [11,18]. No other information concerning Cys residues is available for other Ras isoforms.

---

### Table 1: Cys residues modified on wild-type Ras protein.

| Ras isoform | Chemical modification | Method | References |
|-------------|-----------------------|--------|------------|
| H-Ras       | -nitrosylation (Cys118) | Optical waveguide light-mode spectroscopy | [1] |
| H-Ras       | -nitrosylation (Cys118) | Spectroscopy | [2] |
| H-Ras       | -nitrosylation (Cys118) | LC-MS/MS | [3] |
| H-Ras       | -nitrosylation (Cys118) | MS, immunoblot and immunoprecipitation | [4] |
| H-Ras       | -nitrosylation (Cys118) | Flow cytometry, Time-Lapse Fluorescence | [5] |
| H-Ras       | -nitrosylation (Cys118) | Immunoprecipitation and immunoblotting | [6] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [7] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [8] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [9] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [10] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [11] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [12] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [13] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [14] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [15] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [16] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [17] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [18] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [19] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [20] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [21] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [22] |
| H-Ras       | -nitrosylation (Cys118) | MALDI-TOF/MS | [23] |

---

**Table 1: Modifying redox modifications on wild-type Ras protein.**

- **Ras isoform**
- **Chemical modification**
- **Method**
- **References**

S. Messina, et al. | Table 1 | Effects on Ras expression and phenotypic readouts | [13] |
----------------|--------|---------------------------------|---------|
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | Optical waveguide light-mode spectroscopy | [14] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | Spectroscopy and GTP-bound activation | [15] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | MS, immunoblot and immunoprecipitation | [16] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | Flow cytometry, Time-Lapse Fluorescence | [17] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | Immunoprecipitation and immunoblotting | [18] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | MALDI-TOF/MS | [19] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | MALDI-TOF/MS | [20] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | MALDI-TOF/MS | [21] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | MALDI-TOF/MS | [22] |
Bovine brain cortex tissue and Lipid subventricular zone (SVZ) | -nitrosylation (Cys118) | MALDI-TOF/MS | [23] |
Redox regulation has a profound impact on Ras localization [19–22, 70]. Cell-based studies show that different signalling outputs and phenotypic responses are associated with Ras oxidation, albeit without Cys identification. Studies with fluorescent probes in human cells show that the NO-mediated activation of H-Ras in different subcellular compartments regulates different downstream signalling pathways, which lead to various outcomes in proliferation, differentiation and apoptosis. In particular, in human HUVECs and HeLa cells, H-Ras is activated both at the plasma membrane and at the Golgi by low concentrations of S-nitrosoglutathione, leading to the activation of the Akt and ERK1/2MAPK kinases and promoting cell proliferation [21].

S-nitrosothiols may competitively impair the palmitoylation of H-Ras in mouse fibroblast NIH-3T3 cells, thus preventing its localization to the plasma membrane [19, 22]. Similarly, in prostate cancer cells, hypoxia/hyperoxia regulates prenylation of H-Ras. Exogenous hyperoxia increases the intracellular oxygen concentration and induces the rapid H-Ras translocation from cytosol to the membrane; however, this effect is completely reversed by mevalonate, which is well known to...
induce Ras upregulation [70,71].

5. Redox-sensitive RAS proteins in pathogenesis

5.1. Oncogenic Ras

Oncogenic-RAS activation induces tumorigenesis by intracellular ROS levels, i.e., superoxide [16,58,72,73], ROS-generating NADPH-oxidase NOX4 [74], ROS-generating NADPH-oxidase NOX1 [75], unspecified intracellular ROS [9,76-79], and mitochondrial-derived hydrogen peroxide [80,81].

Oncogenic H-Ras has been shown to promote ROS production in a variety of human cell types, including embryonic lung cells [72], human fibroblasts (Lee et al., 1996), immortalized keratinocytes [79], and mouse and human macrophages and monocytes [82]. In particular, the constitutive expression of the active form of v-H-Ras in immortal rat kidney epithelial cells caused cellular transformation and led to the production of a significantly larger amount of superoxide radicals with respect to wildtype cells. The overexpression of antioxidant enzymes, such as manganese-containing superoxide dismutase (Mn-SOD), effectively inhibited Ras-induced transformation indicating that Ras induces cellular transformation through ROS production [73]. Ecptic expression of mutant H-Ras (Gly12Val) in human diploid fibroblasts increased ROS production [80], and this effect was mainly regulated by NADPH-oxidase (NOX) [7]. Furthermore, the constitutive activation of HRAS in haematopoietic progenitor and cancer cells dramatically increases ROS production via activation of the NADPH oxidase complex [58,74,77].

The induction of ROS (i.e., superoxide) mediated by NOX4 is the key step of K-Ras-driven cellular transformation, genomic instability and tumorigenesis [7,10]. K-Ras orchestrates ROS production by promoting the localization of the NOX1 component p47phox to the plasma membrane. This facilitates the interaction of p47phox with protein kinase-C (PKC) isoforms to mediate cellular transformation [75]. KRAS activation is believed to increase ROS production [81]. In turn, high intracellular levels of ROS appear to contribute to the selective oxidative death of KRAS mutant cells. The conditional expression of the oncogenic KRAS G12D mutant increases the level of cellular ROS favouring the selective killing of KRAS mutant cells [78]. In contrast, oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis in mouse embryonic fibroblasts (MEFs), and in NIH-3T3 cells, it lowers cellular ROS [9]. The association of K-Ras with Bcl-XL on mitochondria promotes apoptosis [83].

Oncogenic NRAS is not directly associated with redox imbalance in cancer. Although oncogenic NRAS is associated with melanoma and lymphoid cancers [50], the quantitative relationship between oncogenic N-Ras expression and ROS production has only been described in myelodysplastic syndromes, myeloproliferative diseases [76], and in CD34+ haematopoietic progenitor cells [58]. Notably, oncogenic NRAS (Gly12Asp) expression promotes the proliferative response mediated by increased ROS production in normal human CD34+ progenitor cells [58], although to a lower extent than HRAS (Gly12Val). Interestingly, NRAS mutations in myelodysplastic syndromes (MDS)/myeloproliferative diseases (MPD) result in ROS production [76].

The role of the redox-sensitive Cys118 has been investigated in mouse tumorigenesis. Both urethane-induced lung tumorigenesis [56] and oncogenic HRAS-driven tumorigenesis (Huang et al., 2015) are sensitive to loss of redox-dependent reactions with Cys118 (Table 2). Specifically, mutation of Cys118 (Cys118Ser) in a mouse model of tumorigenesis reduced lung tumour growth. These studies are of paramount importance in understanding the functional implications of Cys oxidation in cancer and focus on personalized therapy with Cys-directed covalent drugs, specifically in the case of oncogenic KRAS (Gly12Cys) [84-86]. Indeed, S-nitrosylation of the Ras Gly12Cys mutant affects the tumorigenic growth of human and murine cell lines [55] (Table 2). Two research groups have recently targeted the Gly12Cys mutation in the oncoprotein K-Ras-Gly12Cys [84,85]. The Gly12Cys mutation induces conformational changes that favour GTP rather than GDP binding. They have independently found K-Ras-Gly12Cys inhibitors, now in phase one clinical trials, that bind to a “cryptic binding” site in the so-called switch II region, which is located in the vicinity of mutated Cys12. This binding site is distinct from the GTP pocket. One compound allosterically locks K-Ras-Gly12Cys in the GDP-bound, and hence inactive, state and impairs the binding of K-Ras to its downstream target, RAF.

5.2. Non-oncogenic Ras

Compared with cancer, considerably less is known about the involvement of non-oncogenic Ras in redox-based pathology. The role of redox reactions in the pathogenesis of autoimmunity has been largely discussed and several different mechanisms of oxidative damage in several different autoimmune diseases have been reported [87]. Endogenous H-Ras is chronically activated by ROS in skin fibroblasts from patients with systemic sclerosis (SSc), establishing a loop between increased ROS, the Ras/MAPK signalling cascade and the complex phenotype of sclerodema fibroblasts in vivo [88].

Moreover, the involvement of oxidative stress in diabetes-induced retinal degeneration has also been investigated, demonstrating that the accumulation of ROS considerably affects all phases of diabetic retinopathy pathogenesis. In mouse models of this disease, translocation of H-Ras has been indicated as a plausible mechanism responsible for accelerated apoptosis of retinal capillary cells. The administration of simvastatin (an inhibitor of Ras protein prenylation) and silencing of H-Ras inhibit protein translocation to the membrane and pathology development. Further, the overexpression of Mn-SOD in mice prevented diabetes-induced activation of H-Ras [89-91]. In addition, another
member of the Ras family, R-Ras, has been reported to control retinal vessel maturation and stabilization in ischaemic retinopathy [92].

Ischaemia and hypoxia are major players in heart and brain diseases. NO plays a key role in tissue function during hypoxia by regulating the S-nitrosylation of target proteins [93,94], such as Ras and Rho-related GTPases [64]. In particular, under hypoxic conditions, p21Ras is activated by S-nitrosylation initiating the translocation of H-Ras in the cytosol [95]. Interestingly, the endogenous S-nitrosylation of membrane-bound H-Ras does not change during hypoxia in rat pheochromocytoma PC12 cells [20]. Ras protein has been reported to undergo S-thiolation during reperfusion of ischaemic rat heart tissue [23].

In the brain, ischaemia and hypoxia rely on astrocyte function. In fact, astrocytes are specialized CNS oxygen sensors tuned for rapid detection of physiological changes in brain oxygenation [96]. Interestingly, among the mammalian tissues, the highest level of Ras proteins (K-Ras mainly) was detected in the brain [97,98], albeit the protein levels in neurons or associated glial cells are unknown. The exposure of primary astrocytes to exogenous hydrogen peroxide induces an intracellular burst of ROS that mediates different transcriptional, translational and post-translational actions of H-Ras and K-Ras proto-oncogenes [99–101]. Furthermore, trophic deprivation (the main inducer of autophagy) results in the initial increase of intracellular ROS levels [102] and acute H-Ras induction in primary astrocytes [99]. These studies examined the role of two members of the small GTPase family, H-Ras and K-Ras, which are highly expressed in astrocytes, albeit not fully characterized, and suggest that astrocytic Ras-dependent pathways are important mediators for neuroprotective adaptive response to oxidative stress.

Similarly, transcriptional induction of HRAS, NRAS, and KRAS in cultured primary astrocytes is induced by interferon-γ treatment, which is the most potent inducer of ROS-RNS formation in target cells [103]. Moreover, adult human astrocytes stimulated with interferon-γ exert potent neurotoxic effects in vitro [104], possibly reflecting the transient upregulation of HRAS in cultured astrocytes by ROS.

6. Conclusions

The oxidation and reduction of Cys residues provide a mechanism that rapidly and reversibly alters protein functions, albeit at physiological ROS levels. The Cys-based oxidative modification of H-Ras can be extensive in vivo, both S-nitrosylated and S-glutathionylated forms may be important, and oxidation may occur on reactive Cys residues that are usually targeted for lipid-modification reactions. Thus, these chemical modifications could act as antagonists of the physiological processing of the proteins and subsequent proper subcellular localization. Moreover, studies on Cys-directed therapy have increasingly gained attention in personalized cancer therapeutics [86].

Isoform-distinct Ras biological roles in normal and neoplastic cells are increasingly appreciated, but biochemical studies of native proteins are currently lacking. Indeed, the crystallographic structure of full-length proteins is still lacking, as only the structure of K-Ras4B in complex with PDEδ has recently been reported [30]. Many studies use a single isoform (namely, H-Ras); therefore, the lack of evidence for other isoforms does not exclude their involvement in redox biology.

Moreover, site-directed mutagenesis is often employed to determine whether specific Cys residues (mainly Cys118) have redox-regulated functional roles, but this approach provides no information on the oxidation status of the endogenous protein. The generation of oxidized Ras by adding bolus oxidants to cells and the overexpression of recombinant and/or truncated proteins represent significant caveats for the investigation of the redox biology of Ras. Moreover, cell-based studies should be performed with endogenous ROS sources and redox state characterization and be absent of GTPase overexpression. Indeed, redox-sensitive probes targeted to different cellular compartments will revolutionize our understanding of in vivo redox signalling in both time and space [105].

More recently, reactive cysteines have been targeted by high-throughput screening and fragment-based ligand discovery efforts [106]. Specific Cys residues function as redox-dependent switches in most ROS-dependent Ras signalling events. Whether the oxidation state of thiol groups can be harnessed to develop a unique class of redox-sensitive small molecule drugs remains to be seen.

7. Credit authorship contribution statement

Samantha Messina: Conceptualization, writing of the original draft, and funding acquisition. Giovanna De Simone: Structural analysis and writing of the original draft. Paolo Ascenzi: Review and supervision.

Conflicts of interest

The authors declare that there are no competing interests associated with this manuscript.

Acknowledgements Funding

The Grant of Excellence Departments, MIUR (Articolo 1, Commi 314–337 Legge 232/2016), is gratefully acknowledged.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.redox.2019.101282.

References

[1] J.V. Cross, D.J. Templeton, Regulation of signal transduction through protein cysteine oxidation, Antioxidants Redox Signal. 8 (2006) 1819–1827.
[2] T. Finkel, Intracellular redox regulation by the family of small GTPases, Antioxidants Redox Signal. 8 (2006) 1857–1865.
[3] M.F. Davis, D. Vigil, S.L. Campbell, Regulation of Ras proteins by reactive nitrogen species, Free Radic. Biol. Med. 51 (2011) 565–575.
[4] J. Heo, Redox control of GTPases: from molecular mechanisms to functional significance in health and disease, Antioxidants Redox Signal. 14 (2011) 689–724.
[5] L. Mitchell, G.A. Hobbs, A. Aghajanian, S.L. Campbell, Redox regulation of Ras and Rho GTPases: mechanism and function, Antioxidants Redox Signal. 18 (2013) 250–258.
[6] E. Ferro, L. Goitre, E. Baldini, S.F. Retta, L. Trabalzini, Ras GTPases are both regulators and effectors of redox agents, Methods Mol. Biol. 1120 (2014) 55–74.
[7] K. Irani, Y. Xia, J.L. Zweier, S.J. Sollott, C.J. Der, E.R. Fearon, M. Sundaresan, T. Finkel, P.J. Goldschmidt-Clermont, Mitogenic signaling mediated by antioxidants in Ras-transformed fibroblasts, Science 275 (1997) 1649–1652.
[8] F. Weinberg, R. Hamanaka, W.W. Wheaton, S. Weinberg, J. Joseph, M. Lopez, B. Kalyanaraman, G.M. Mutlu, G.R. Budinger, N.S. Chandel, Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenesis, Proc. Natl. Acad. Sci. U.S.A. 107 (2010) 8788–8793.
[9] G.M. De Nicola, F.A. Karreth, T.J. Hampton, A. Gopinathan, C. Wei, K. Frese, D. Mangal, K.H. Yu, C.J. Yeo, E.S. Calhoun, F. Scrimieri, J.M. Winter, R.H. Hruban, C. Iacobuzio-Donahue, S.E. Kern, I.A. Blair, D.A. Tuveson, Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis, Nature 475 (2011) 106–109.
[10] M. Ogrunc, R. Di Micco, M. Liontos, L. Bombardelli, M. Mione, F. Umezaki, V.G. Gorgoulis, F. d’Adda di Fagagna, Oncogene-induced reactive oxygen species fuel hyperpliorferesis and DNA damage response activation, Cell Death Differ. 21 (2014) 998–1012.
[11] T. Adachi, D.R. Pimentel, T. Heiback, X. Hou, Y.J. Lee, B. Jiang, Y. Ido, R.A. Cohen, S-glutathiolation of Ras mediates redox-sensitive signalling by angiotensin II in vascular smooth muscle cells, J. Biol. Chem. 279 (2004) 29857–29862.
[12] N. Clavreul, T. Adachi, D.R. Pimentel, Y. Ido, C. Schöneich, R.A. Cohen, S-glutathiolation by peroxynitrite of p21ras at cysteine-118 mediates its direct activation and downstream signalling in endothelial cells, PASEB J. 20 (2006) S186-S200.
[13] L. Shanbhagulkol, N. Narmania, T. Barbakadze, E. Zhuravliova, N. Navsulidivili, J. Ramsden, D.G. Mikeladze, S. Nitrosylation decreases the adsorption of H-Ras in lipid bilayer and changes intrinsic catalytic activity, Cell Biochem. Biophys. 59 (2011) 191–199.
[14] A.I. Santos, B.P. Carreira, A. Izquierdo-Álvarez, E. Ramos, A.S. Lourenço, D. Filipa Santos, M.I. Morte, L.F. Ribeiro, A. Marreiros, N. Sánchez-López, A. Marina, C.M. Carvalho, A. Martinez-Ruiz, I.M. Arazuín, S-nitrosylation of Ras mediates nitric oxide-dependent post-injury neurogenesis in a seizure model, Antioxidants Redox Signal. 28 (2018) 15–30.
[15] N. Ntai, L. Fornelli, C.J. DeHart, J.E. Hutton, P.F. Doubleday, R.D. LeDuc, A.J. van...
primary antioxidant enzymes, Antioxidants Redox Signal. 3 (2001) 697–709.

U. Weyemi, O. Lagente-Chevalier, M. Bourfaqech, F. Frenois, F. Courtin, B. Caillou, M. Talbot, M. Dardalhon, A. Al Ghuzlan, J.M. Bidart, M. Schlumberger, C. Dupuy, ROS-generating NADPH oxidase NOX1 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence, Oncogene 31 (2012) 1117–1129.

M.T. Park, M.J. Kim, Y. Suh, R.R. Kim, H. Kim, E.J. Lim, K.C. Yoo, G.H. Lee, Y.H. Kim, S.G. Hwang, J.M. Yi, S.J. Lee, Novel signaling axis for ROS generation during K-Ras-induced cellular transformation, Cell Death Differ. 21 (2014) 1185–1197.

F.V. Rassool, T.J. Gaymes, N. Omidvar, N. Brady, S. Beurlet, M. Pla, M. Rebold, N. Lea, C. Chomienne, N.S. Thomas, G.J. Muñoz, R.A. Padua, Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res. 67 (2007) 8762–8771.

Y. Adachi, Y. Shiabit, J. Mitsuhashi, W.H. Shang, K. Hirose, T. Kamata, Oncogenic Ras upregulates NADPH oxidase 1 gene expression through MEK-ERK-dependent phosphorylation of GATA-6, Oncogene 27 (2008) 4941–4952.

A.T. Shaw, M.M. Winslow, M. Magendantz, C. Ouyang, J. Dowdle, A. Subramanian, T.A. Lewis, R.L. Maglathlin, N. Tolliday, T. Jacks, Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress, Proc. Natl. Acad. Sci. U.S.A. 108 (2011) 8773–8778.

M. Zamanova, N. Khromova, B.P. Kopnin, P. Kopnin, Ras-induced ROS upregulation affecting cell proliferation is connected with cell type-specific alterations of HSFI/SESNN3/p21CIP1/WAF1 pathways, Cell Cycle 12 (2013) 826–836.

A.C. Lee, B.E. Fenster, H. Ito, K. Takeda, N.S. Iba, T. Hirai, Y. Yu, V.J. Ferrans, B.H. Howard, T. Finkel, Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species, J. Biol. Chem. 274 (1999) 7936–7940.

D. Trachootham, Y. Zhou, H. Zhang, Y. Demizu, Z. Chen, H. Pelicano, P.F. Chiao, G. Achatz, R.B. Arlinghaus, J. Liu, P. Huang, Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate, Cancer Cell 10 (2006) 241–252.

W.K. Besler, E.Z. Hudson, H. Zhang, V. Harris, Y. Wang, J.A. Mund, B.K. Stanfield, Neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans, Free Radic. Biol. Med. 97 (2016) 212–222.

T.G. Bivona, S.E. Quatela, B.O. Bodemann, I.M. Ahearn, M.J. Soksis, A. Mor, J. Mizra, H.H. Wiener, L. Wright, S.G. Saba, D. Yim, A. Fein, I. Pérez de Castro, B.K. Stansfield, neurofibromin is a novel regulator of Ras-induced reactive oxygen species production in mice and humans, Free Radic. Biol. Med. 97 (2016) 212–222.

J.J. Ho, H.S. Man, P.A. Marsden, Nitric oxide signaling in hypoxia, J. Mol. Med. 364 (2010) 422–435.

G. Maulucci, G. Battaglia, P. Spinsanti, A. Di Pardo, F. Sievers, D.G. Higgins, Clustal omega, Curr. Protoc. Bioinformatics 48 (2014) 3–204.

J.M. Ostrem, U. Peters, M.L. Sos, J.A. Wells, K-M. Shokat, K-Ras(G12C) inhibitors allosterically control GTTP affinity and effector interactions, Nature 503 (2013) 548–551.

S.M. Lim, K.D. Westover, S.B. Picarzo, R.A. Harrison, H.G. Choi, M.E. Pacold, M. Carrasco, J. Hunter, N.D. Kim, X. Tie, S. Tim, P.A. Jänne, M. Meyerson, J.A. Marto, J.R. Engen, N.S. Gray, Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor, Angew. Chem. Int. Ed. Engl. 53 (2014) 199–204.

M. Visscher, M.R. Philips, PKC regulates a farnesyl-electrostatic cation interactions, Nature 503 (2013) 8778.

S. Messina, G. Molinaro, V. Bruno, G. Battaglia, P. Spinossi, A. Díez-Parrón, N. Lea, C. Chomienne, N.S. Thomas, G.J. Mufti, R.A. Padua, Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res. 67 (2007) 8762–8771.

E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, A. Vajargah, Adjusting amino acid substitution matrices from protein blocks, Protein Sci. 21 (2012) 10919–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

D. Flitschinski, O. Shabari, A. Rüppel, I.R. Vetter, C. Herrmann, J.M. Shifman, What makes Ras an efficient molecular switch: a computational, biological, and structural study of Ras-GDP interactions with mutants of Raf, J. Mol. Biol. 399 (2010) 422–435.

E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, A. Vajargah, Adjusting amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Konrad, J. Zwicker, A.G. Teschemacher, G.L. Ackland, G.D. Funk, S. Kasparov, A.Y. Abramov, A.V. Gourine, Functional oxygen sensitivity of astrocytes, J. Neurosci. 35 (2015) 10460–10473.

M.E. Furth, T.H. Aldrich, C. Gordon-Cardo, Expression of ras proto-oncogene proteins in normal human tissues, Oncogene 1 (1987) 47–58.

A. Mizia, V. Balas, E. Aicardi, A. Aicardi, C. Chomienne, N.S. Thomas, G.J. Mufti, R.A. Padua, Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia? Cancer Res. 67 (2007) 8762–8771.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.

S. Henikoff, J.G. Henikoff, Amino acid substitution matrices from protein blocks, Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10915–10919.